PhRMA's Scott LaGanga discusses the expanding influence of state policymaking on drug pricing, PBM reform, and efforts to translate policy changes into lower out-of-pocket costs for patients.
Feature|Articles|September 2, 2026
Redefining Medical Strategy in Obesity Through Real-World iNSIGHTS
Author(s)Lexi Cogswell, PhD, Tom Rotolo, PhD
Real-world evidence tells you what happened. Real-World iNSIGHTS tell you why — and what to do next. A new framework for medical affairs.
Advertisement
Advertisement
As the healthcare community grapples with rising obesity rates, medical strategy generation is undergoing its most significant evolution in decades, moving away from a traditional model of data dissemination toward a future defined by strategic intelligence. To meet the challenges of this complex therapeutic area, pharmaceutical organizations must look beyond traditional data sources and embrace a new way: supporting the generation of Real-World iNSIGHTS.
Related to this article
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
As Medicare negotiation, PBM reform, and cash-pay channels converge, winning on auditable net value matters more than cutting list prices.
Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its research collaboration with Korro Bio, and the FDA grants accelerated approval to Johnson & Johnson’s Rybrevant Faspro in head and neck cancer.
The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per month without leaving the platform.
The termination ends a cardiometabolic RNA-editing partnership that was paused for 12 months, closing out a deal under which Korro earned no milestone payments.
Accelerated approval of subcutaneous Rybrevant Faspro (amivantamab) based on a 42% response rate in 102 patients; a phase 3 confirmatory trial is under way.
When tumors shift, old treatments stop working. Dr. Brian Corgiat explains why real-time tumor profiling is critical to effective therapy.
Advertisement
Advertisement